接受铂类化疗的妇科癌症患者补充蛋白质、亮氨酸和维生素 D (PRODIGY-1)
接受一线铂类化疗的妇科癌症患者补充蛋白质、亮氨酸和维生素 D
Open clinical trial addressing the effect of a nutritional support based on whey proteins, leucine and vitamin D on muscle mass and multiple anticancer treatment-related endpoints in patients with gynecologic cancer receiving first-line platinum-based chemotherapy (adjuvant or curative). A comparison to matched historical controls will be performed to address potential evidence of efficacy to be investigated in a subsequent randomized trial.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Riccardo Caccialanza, MD
- 电话号码:+390382501615
- 邮箱:r.caccialanza@smatteo.pv.it
研究联系人备份
- 姓名:Emanuele Cereda, MD, PhD
- 电话号码:+390382501615
- 邮箱:e.cereda@smatteo.pv.it
学习地点
-
-
Italy
-
Pavia、Italy、意大利、27100
- 招聘中
- IRCCS San Matteo
-
首席研究员:
- Emanuele Cereda, MD, PhD
-
接触:
- Emanuele Cereda, MD, PhD
- 电话号码:+390382501615
- 邮箱:e.cereda@smatteo.pv.it
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- histologically confirmed diagnosis of gynecologic cancer (ovarian, uterine, cervical);
- indication for a first-line chemotherapy (adjuvant or curative) with a platinum-based regimen to be used by investigator's choice within the framework of good clinical practice and in agreement with current Italian Association of Medical Oncology guidelines;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
- signed informed consent.
Exclusion Criteria:
- age <18 years
- ECOG performance status >2
- indication to or ongoing artificial nutrition support
- known kidney failure (previous glomerular filtration rate <30 ml/min);
- known liver failure (Child B or C)
- endocrine disorders associated with disorders of calcium metabolism (excluding osteoporosis)
- decompensated diabetes
- indications related to the study product: more than 10 µg (400 IU) of daily Vitamin D intake from medical sources More than 500 mg of daily calcium intake from medical sources; adherence to a high energy or high protein diet up or use of protein containing or amino acid containing nutritional supplements up to three months before starting the study.
- known allergy to milk, milk products or other components of the proposed interventions
- inclusion in other nutritional intervention trials
- patients refusal
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Muscle-targeted nutritional support
Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers. |
Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
其他名称:
|
|
其他:Standard of care
Control group receiving no nutritional intervention or on-demand non muscle-targeted nutritional intervention such as nutritional counseling with or without oral nutritional supplement |
Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in muscle mass area
大体时间:18 weeks
|
Change in muscle mass at the end of first-line platinum-based chemotherapy (adjuvant or curative) evaluated with computed tomography scan at the level of the third lumbar vertebra |
18 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Skeletal muscle mass
大体时间:18 weeks
|
Change in skeletal muscle mass during the study evaluated with bioimpedance vectorial analysis |
18 weeks
|
|
Body weight
大体时间:18 weeks
|
Change in body weight during the study (assessed at each chemotherapy cycle) |
18 weeks
|
|
Protein-calorie intake
大体时间:18 weeks
|
Change in protein-calorie intake during the study (assessed at each chemotherapy cycle) |
18 weeks
|
|
Handgrip strength
大体时间:18 weeks
|
Change in handgrip strength |
18 weeks
|
|
Treatment-related moderate-severe adverse events as assessed by Common Terminology Criteria for Adverse Events [CTCAE v5.0]
大体时间:18 weeks
|
Difference in the incidence of grade >=3 toxicity, according to CTCAE v5.0. Toxicity is graded on 0-5 ordinal scale where a higher score means a worse outcome. |
18 weeks
|
|
Adherence to treatment schedule
大体时间:18 weeks
|
Difference in the proportion of patients completing the treatment schedule as planned |
18 weeks
|
|
Total dose of chemotherapy administered
大体时间:18 weeks
|
To be calculated as the percentage of chemotherapy dose administered with respect to the treatment plan |
18 weeks
|
|
Patients requiring unplanned hospitalization
大体时间:18 weeks
|
The rate of patients requiring unplanned hospitalization (one or more) during the study will be calculated |
18 weeks
|
|
Tolerance to nutritional support
大体时间:18 weeks
|
Occurrence of events of gastrointestinal intolerance |
18 weeks
|
合作者和调查者
调查人员
- 首席研究员:Emanuele Cereda, MD, PhD、Fondazione IRCCS Policlinico San Matteo
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 0014137/23
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.